Pontocerebellar hypoplasia due to bi-allelic variants in MINPP1. by Appelhof, B et al.
European Journal of Human Genetics
https://doi.org/10.1038/s41431-020-00749-x
ARTICLE
Pontocerebellar hypoplasia due to bi-allelic variants in MINPP1
Bart Appelhof1 ● Matias Wagner 2,3 ● Julia Hoefele3 ● Anja Heinze4 ● Timo Roser5 ● Margarete Koch-Hogrebe6 ●
Stefan D. Roosendaal 7 ● Mohammadreza Dehghani8 ● Mohammad Yahya Vahidi Mehrjardi8 ● Erin Torti9 ●
Henry Houlden 10 ● Reza Maroofian10 ● Farrah Rajabi11 ● Heinrich Sticht12 ● Frank Baas1 ● Dagmar Wieczorek13 ●
Rami Abou Jamra 4
Received: 25 June 2020 / Revised: 11 September 2020 / Accepted: 22 September 2020
© The Author(s) 2020. This article is published with open access
Abstract
Pontocerebellar hypoplasia (PCH) describes a group of rare heterogeneous neurodegenerative diseases with prenatal onset. Here we
describe eight children with PCH from four unrelated families harboring the homozygous MINPP1 (NM_004897.4) variants;
c.75_94del, p.(Leu27Argfs*39), c.851 C >A, p.(Ala284Asp), c.1210C >T, p.(Arg404*), and c.992 T >G, p.(Ile331Ser). The
homozygous p.(Leu27Argfs*39) change is predicted to result in a complete absence of MINPP1. The p.(Arg404*) would likely lead
to a nonsense mediated decay, or alternatively, a loss of several secondary structure elements impairing protein folding. The
missense p.(Ala284Asp) affects a buried, hydrophobic residue within the globular domain. The introduction of aspartic acid is
energetically highly unfavorable and therefore predicted to cause a significant reduction in protein stability. The missense p.
(Ile331Ser) affects the tight hydrophobic interactions of the isoleucine by the disruption of the polar side chain of serine, destabilizing
the structure of MINPP1. The overlap of the above-mentioned genotypes and phenotypes is highly improbable by chance. MINPP1
is the only enzyme that hydrolyses inositol phosphates in the endoplasmic reticulum lumen and several studies support its role in
stress induced apoptosis. The pathomechanism explaining the disease mechanism remains unknown, however several others genes
of the inositol phosphatase metabolism (e.g., INPP5K, FIG4, INPP5E, ITPR1) are correlated with phenotypes of
neurodevelopmental disorders. Taken together, we presentMINPP1 as a novel autosomal recessive pontocerebellar hypoplasia gene.
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Introduction
Pontocerebellar hypoplasia (PCH) describes a spectrum of
rare genetic neurodegenerative disorders, which are hall-
marked by a combination of early atrophy and hypoplasia of
the pons and cerebellum. Clinical signs occur within the
first months of life and include severe motor and cognitive
impairments [1]. Progressive microcephaly is observed and
patients often die young. PCH is an extremely rare disease.
Hitherto, 13 subtypes have been identified with distinct
clinical features or genetic aberration in one of the 19 PCH
related genes [2]. Relatively common subtypes are well
characterized, i.e., PCH2 (OMIM #277470) is characterized
by an invariable pontocerebellar hypoplasia with severe
motor and cognitive delay and PCH1 (OMIM # 614678)
patients show a PCH2/SMA-like phenotype [3]. However,
most subtypes are very rare and only few patients or gen-
otypes are described [4–7]. Still, a molecular diagnosis can
be achieved in not all PCH cases. The identification of the
causative genetic variant is essential for the counseling of
the families and important for the prognosis and recurrence
risk.
The mechanisms underlying PCH are not well under-
stood. The initial identification of recessive pathogenic
variants in genes encoding tRNA splicing endonuclease
(TSEN) complex suggested a link between tRNA proces-
sing and cerebellar development (TSEN54, TSEN2,
TSEN15, TSEN34, SEPSECS, RARS2, and CLP1). How-
ever, the identification of other RNA processing genes
(TOE1, VRK1, EXOSC3, EXOSC8, EXOSC9) suggested
that the defects are not restricted to tRNA processing and
even variants in genes not involved in RNA processing at
all may lead to PCH (CHMP1A, TBC1D23, PCLO, VPS53,
SLC25A46, COASY) [5, 7–16].
In this study, we describe four different homozygous
variants in the multiple inositol polyphosphate phosphatase
1 (MINPP1) gene in patients with PCH. The encoded pro-
tein MINPP1 (OMIM *605391) is located in the endo-
plasmic reticulum (ER) lumen where it removes 3-
phosphates from inositol substrates [17]. Thus far
MINPP1 has not been linked to any human disease.
Materials and methods
Ethical approval
Patients were enrolled and sampled according to standard
local practice in approved human subjects protocols as part
of routine clinical care at the respective Institutes. The
project was approved by the Ethic Committee of the Uni-
versity of Leipzig, Germany (224/16-ek and 402/16-ek) and
the Technical University Munich, Germany (#5360/12 S)
and was conducted in concordance to the declaration of
Helsinki. Written informed consent of all examined indi-
viduals or their legal representatives for genetic testing and
the publication of findings was obtained after advice and
information about the risks and benefits of the study.
Families were identified via the online match making plat-
form GeneMatcher [18].
Exome sequencing
For all four families, trio exome sequencing has been per-
formed. As the families come from different centers and
have been examined in different time spans, the methods of
the exome sequencing differ. Exome capture was carried
out with BGI Exome kit capture (59M), Agilent Sureselect
50Mb V5 kit, and Nimblegen Seqcap EZ exome enrich-
ment, for families 1, 2, and 3, respectively. Sequencing was
performed on a BGISEQ-500, Illumina HiSeq2500 plat-
form, and a SOLiD 5500 platform, respectively. Coverage
of at least 10x has been achieved in 98.0%–98.5%,
98.4%–98.7%, and 87.2%–90.0% for the sequenced family
members in the families 1, 2, and 3, respectively. Exome
sequencing and variant analysis for family 4 was performed
as previously described [19].
Variant prioritization
For family 1, analysis of the raw data was performed using
the software Varfeed (Limbus, Rostock) and the variants
were annotated and prioritized using the software Varvis
(Limbus, Rostock). For family 2 data analysis was done
using a custom built bioinformatic pipeline as previously
described [20]. For family 3 we performed the analysis
using the Ingenuity Variant Analysis™ software (Qiagen,
Redwood city).
We have evaluated all annotated variants as well as rare
(minor allele frequency below 1%) potential protein-
influencing variants in mutation databases (primarily
HGMD and ClinVar [21, 22]). We prioritized the variants
based on minor allele frequency, inheritance mode, and
potential predicted pathogenicity (including in silico
values). As no pathogenic or likely pathogenic bi-allelic
variants were identified and the families consented for
research, we continued evaluation of the sequencing data in
a scientific setting in order to identify variants in novel
candidate genes. The identified variants were prioritized
based on the above mentioned parameters as well as on
attributes of the genes, including functional plausibility of
the gene, its tolerance for variants (i.e., LOEUF value and Z
score [23]), and further aspects (including available animal
models, interaction partners, plausibility of the symptoms in
regard to the function of the gene).
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3D modeling of variants
Modeling of the MINPP1 structure was performed with
HHpred and Modeler using the structure of Phytase in
complex with myo-inositol hexakis sulfate (PDB: 3K4Q) as
a template [24–26]. Modeling and evaluation of the variant
p.(Ala284Asp) and p.(Ile331Ser) was done with VIPUR
[27]. RasMol was used for structure analysis and visuali-
zation [28].
Results
Clinical description
Family 1
The unaffected parents originate from the same small town
in Bosnia and have three sons. The older brother is not
affected, and the two younger brothers are affected.
Pregnancy of the male proband (1–1) from family 1
(Fig. 1b) was uneventful. He was born in the 37+ 0 week of
gestation (birth weight 2105 g (−2.2 SD), length 44 cm
(−2.6 SD), head circumference 31 cm (−2.3 SD)). In the first
few months, he showed muscular hypertonia. The first pre-
sentation in the clinic was at age of 6 months as he had
suffered from seizures. He weighed 5920 g (−1.9 SD), was
60 cm long (−2.7 SD) and showed a remarkable progressive
microcephaly with a head circumference of 37 cm (−5.7
SD). Brain MRI revealed a pontocerebellar hypoplasia with a
very small pons and reduced volume of the thalamus and
basal nuclei. Also, a thin corpus callosum and a dilation of
the ventricles and peripheral cerebrospinal fluid (CSF) spaces
were observed (Fig. 1C). Severe developmental delay fol-
lowed and he achieved none of the milestones (no sitting,
standing, walking, and speech). Epilepsy was refractory with
a permanent seizure activity. EEG showed epilepsy with
salaam attacks. Furthermore, he showed stereotypic move-
ments and ataxia. He was severely affected, suffered from
recurrent infections and had a percutaneous endoscopic
Fig. 1 Pedigrees of the families and MRI of the affected children.
a Pedigrees of the four families showing recessive inheritance pattern.
Patient 1-1 is deceased at the age of 32 months. Patient 3-1 received
two copies of chromosome 10 from his mother, which lead to an
acquired homozygosity. b Picture of patient 1-1 and patient 4-2 (c)
Brain MRI of all eight patients, sagittal (top), coronal (middle) and
axial (bottom). The decreased size of the cerebellum is indicated by the
yellow arrow. A small pons is seen and on the axial images a
decreased size is seen from the caudate nuclei in all patients.
Pontocerebellar hypoplasia due to bi-allelic variants in MINPP1
gastrostomy (PEG). He had a micropenis, but no other
abnormal clinical findings (no facial dysmorphisms, no
abnormalities on ophthalmological examinations and hearing
test, apart from possible hyperacusis). He died at the age of
32 months due to an influenza virus infection.
His younger brother (patient 1-2) was born after an
uneventful pregnancy at 41 weeks of gestation with a
weight of 3645 g (−0.2 SD), length 51 cm (−0.9 SD), and
head circumference of 33.5 cm (−1.9 SD). Until the age
of 6 months, the parents reported muscular hypertonia
and agitation, similar to his brother. At the age of
11 months, his weight was 7100 g (−2.3 SD), length 73
cm (−0.8 SD), and head circumference 38.8 cm (−6.6
SD). He did not have seizures, but presented with sig-
nificantly delayed development. In addition, he presented
stereotypic movements, agitations, stiffness, spasticity,
and ataxia. Therefore, he had a markedly similar pheno-
type to his elder brother before the seizures started. A
brain MRI showed similar though milder abnormalities
(Fig. 1c). He also has a micropenis, but no other dys-
morphologies. Hearing test showed no abnormalities,
apart from possible hyperacusis as he startles often and
has an impressive Moro reflex. He generally does better
than his brother, has no recurrent infections, and does not
require tube feeding.
Family 2
Patient 2-2 is a girl that was born as second child to
consanguineous parents of Turkish origin at term after an
uneventful pregnancy (birth weight 4290 g (+2.4 SD),
length 54 cm (+1.1 SD), head circumference 36 cm
(+1.7 SD)). From early on, she showed a slow develop-
ment and was able to sit at age 16 months and walked
independently 4 months later. She developed secondary
microcephaly in the first years. Examination at the age of
8 years revealed generalized hypotonia, ataxia and dys-
morphic features with wide nasal bridge, arched eye-
brows, up slanting palpebral fissures, epiblepharon, and
diastema of the upper incisors. She speaks ~20 words.
Brain MRI showed pontocerebellar hypoplasia (see
Table 1). The thalami were slightly small, though the
basal ganglia were normal. Dilated frontal CSF spaces
indicated possible hypoplasia of the frontal lobes
(Fig. 1c). She developed bilateral cataracts in toddler age
and artificial lenses were inserted at age 3 years. She
suffered from refractory seizures since the age of 4 years.
EEGs showed continuous generalized slow spike-waves
in sleep.
The patient’s older sister (patient 2-1) has intellectual
disability, disruptive behavior disorder and bilateral con-
genital cataracts. At her last visit at age 4 years, she had no
ataxia and a normal head circumference. Brain MRI showed
a left temporal arachnoid cyst (size 2.8 × 1.7 × 2.0 cm), and
pontocerebellar hypoplasia (Fig. 1c). Like her sister possi-
ble atrophy of the frontal lobes indicated by the dilated
peripheral CSF space was noticed. The ventricles were
mildly dilated. EEG and cardiac ultrasound were normal, as
well as metabolic studies.
Family 3
Patient 3-1 is a boy who was born to non-consanguineous
parents of whom the mother is of Serbian and the father of
Dutch origin. He was born at 41 weeks of gestation fol-
lowing an uneventful pregnancy (birth weight 4270 g (+1.4
SD), length and head circumference were not assessed). The
boy was born with a micropenis with palpable testis and a
bilateral congenital blepharoptosis. No other malformations
were seen. At two months the blepharoptosis was surgically
corrected and a lack of eye contact was noted. At four
months epileptic seizures with salaam attacks occurred with
a frequency of four to five times per day. These could have
been present since birth and are treated with Mogadon.
Other symptoms included nystagmus. At the age of
8 months, his weight was 9200 g (+0.3 SD), length 77 cm
(+2.4 SD), and head circumference 43.3 cm (−1.1 SD). He
suffered from therapy refractory epilepsy and severe axial
hypotonia with hypertonia of the extremities. Feeding was
unremarkable and no PEG was needed. Brain MRI at age of
five months showed pontocerebellar hypoplasia, with a very
small pons and very small basal nuclei and thalamus
(Fig. 1c). The corpus callosum was thin and there was
possibly white matter atrophy. Also, the ventricles were
severely dilated. EEG showed hypsarrhythmia.
Family 4
Patient 4-1 is the first-born to consanguineous Iranian
parents. He was born at term after an unremarkable preg-
nancy. His birth weight was 2900 g (−0.54 SD), length 49
cm (−0.11 SD), and head circumference 34 cm (−0.02
SD). Since the first years of life, ataxia and hypotonia were
observed. The patient had profound intellectual disability,
he was nonverbal and unable to sit by the age of 10 years.
He was also diagnosed with cortical blindness. Physical
examination revealed axial hypotonia and appendicular
spasticity, with a very restricted range of voluntary
movements. Brain MRI revealed atrophy of the vermis and
pons with sparing of the cerebellar hemispheres (Fig. 1c),
T2-weighted hyperintensity of the basal ganglia, atrophy
of the dorsal striatum, enlarged ventricles, and severe
frontal white matter atrophy. EEG showed a polyspike
pattern.
B. Appelhof et al.
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The two younger monozygotic twin brothers of Patient
4-1 (Patients 4-2 and 4-3, Fig.1b) were similarly affected.
They were born at 37 weeks’ gestation after an unremark-
able pregnancy. Birth weights were 2500 g (−1.49 SD) and
2300 g (−1.94 SD), lengths 42 cm (−3.16 SD) and 45 cm
(−2 SD), and head circumferences 32 cm (−1.59 SD) and
31 cm (−2.32 SD) for Patients 4-2 and 4-3, respectively.
Both children were diagnosed with severe intellectual dis-
ability, ataxia and cortical blindness. At the age of
6 months, they started to suffer from epileptic seizures
B
D
Signal peptide
ER retention signal
1 30 487484
p.(Leu27Argfs*39)
Family 1
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Family 2
p.(Arg404*)
Family 3
p.(Ile331Ser)
Family 4
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NM_001178117.1
c.75_94del c.851C>A c.1210C>T
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F
Fig. 2 Molecular modeling. Locations of the variants in MINPP1
gene (a) and protein (b). Model of the MINPP1 structure (c–h)
illustrating the effect of truncation and missense variants and the
location of the variants on the gene. c Structure of MINPP1 (backbone
representation) showing the location of p.A284 (blue) and the bound
InsP6 substrate (stick representation). Also, the p.Arg404* truncation
variant causes the loss of several elements in secondary structure
(missing elements are indicated in cyan). d Structure of MINPP1
(backbone representation) showing the location of p.Iso331 (blue) and
the bound InsP6 substrate (stick representation). e p.Ala284 is buried in
the hydrophobic core of MINPP1. p.Ala284 is colored according to the
atom types and the interacting hydrophobic residues are shown in dark
gray. f In the p.Ala284Asp variant a charged carboxyl group is placed
within the hydrophobic protein core (color coding as in (e)). f and g p.
Iso331 forms tight hydrophobic interactions with the aromatic residues
p.Phe235 and p.Tyr329, and with the hydrophobic methylene groups
of the p.Glu474 sidechain. p.Iso331 is colored according to the atom
types and the interacting residues are shown in dark gray. h In the p.
Iso331Ser variant the smaller polar serine sidechain is placed within
the hydrophobic environment leading to a destabilization of the
MINPP1 structure (color coding as in (g)).
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which only partially responded to antiepileptic treatment,
with a frequency of once a month. At the age of 7 years,
both children were nonverbal and unable to sit. Physical
examination revealed severe axial hypotonia and spastic
tetraplegia. Neuroimaging findings were very similar to
those observed in the older brother, except for a sparing of
the putamen and caudate nucleus in patient 4-2. EEG
revealed a polyspike and wave pattern in both twins.
Genetic results
Whole Exome Sequencing revealed exonic variants in
MINPP1 (NM_004897.5) in all patients (Fig. 2a). In
both affected boys of family 1 a homozygous frameshift
variant c.75_94del, p.(Leu27Argfs*39) was identified,
their parents were heterozygous carrier for this variant. In
family 2, a homozygous missense variant c.[851 C > A],
p.(Ala284Asp) was identified in both affected sisters, their
parents were also heterozygous carrier. In family 3, a
homozygous nonsense variant c.1210 C > T, p.(Arg404*)
was identified in the patient. The mother was heterozygous
and the father did not carry the variant. Further inspection of
the data revealed a maternal isodisomy of chromosome 10
which was confirmed by SNP array analysis. In the three
siblings from family 4 the homozygous missense variant
c.992 T > G, p.(Ile331Ser) was identified.
The variant detected in family 1 was reported in a het-
erozygous state in two persons in gnomAD (MAF of
0.000008 [23],). The variant of family 2 was present in 25
alleles (MAF of 0.00009) of the gnomAD database but
never reported in homozygous state. The variant of family 3
was present in gnomAD with one allele (MAF of
0.000004). The variant from family 4 has not been reported
before.
Structural analysis
Since cell lines of the patients were not available for
functional analysis, we mapped the identified predicted
protein changes on the MINPP1 structure. The frameshift
caused by the variant p.(Leu27Argfs*39) is located within
the MINPP1 signal peptide that spans residues 1-30
(Fig. 2b). Therefore, this variant is expected to result in
the complete absence of MINPP1. 3D modeling of the
protein reveals that the MINPP1 adopts a well-defined
three-dimensional structure that also harbors the central
ligand binding site (Fig. 2c). The variant c.1210 C > T,
predicted to result in p.(Arg404*), identified in family 3
would possibly lead to nonsense mediated decay. However,
because the c.1210 C > T variant is located in the last exon
of MINPP1, a truncated protein (p.(Arg404*)) could be
translated, but would result in loss of several secondary
structure elements (Fig. 2c). This would likely cause
unfolding of the protein and a loss in enzymatic activity.
The p.(Ala284Asp) missense substitution affects a residue
that is buried within the globular domain of MINPP1
(Fig. 2c). A closer inspection of the structure shows that
A284 forms hydrophobic interactions with the adjacent
residues L105, L276, I281, and F305 (Fig. 2e). In the
A284D variant a charged carboxyl group is placed
within the hydrophobic core (Fig. 2f), which is energetically
highly unfavorable and therefore predicted to cause a sig-
nificant reduction in protein stability and enzymatic activity.
As to the p.(Ile331Ser) missense substitution, the I331
interacts with the hydrophobic methylene groups of the
p.E474 sidechain and with aromatic residues p.F235 and
p.Y329. The p.(Ile331Ser) substitution leads to the place-
ment of a hydrophilic side chain in the hydrophobic
environment. Therefore, it is likely that the p.(Ile331Ser)
substitution disrupts the protein structure.
Discussion
Here we describe eight children from four unrelated families
with development delay and a specific phenotype over-
lapping PCH (Table 1 and Fig. 1). Overlapping clinical
signs include microcephaly or smaller than average head
circumference, epilepsy, micropenis, cataract, ataxia, mus-
cular hyper- and hypotonia, and stereotypies (see Table 1
for further details).
Exome sequencing revealed in all eight affected indivi-
duals homozygous, seemingly pathogenic variants in
MINPP1. In patients 1-1, 1-2, and 3-1 from families 1 and
3, homozygous truncating variants were identified and are
most probably pathogenic. In patients 2-1 2-2, 4-1, 4-2 and
4-3 from family 2 and 4 two homozygous missense variants
assumed to be deleterious based on structural analysis were
identified.
The minor allele frequency of all MINPP1 loss of
function (LoF) variants in gnomAD is 1:6500 and there are
no homozygous LoF. Assuming that the first identified LoF
in this study is not relevant to the phenotype, the probability
of identifying a second homozygous LoF in a cohort of
50,000 cases (there are 44,000 entries in GeneMatcher) by
chance is 0.0082, making a coincidental event highly
improbable.
The above-mentioned lines of evidence let us conclude
that MINPP1 is a strong candidate gene for syndromic
pontocerebellar hypoplasia due to bi-allelic LoF variants.
The three male patients from families 1 and 3 presented
with a micropenis. However, the two sisters of family 2 and
the three male patients from family 4 did not show a disorder
of genitalia. At least two neurological disorders with PCH
have already been observed in combination with a disorder of
sexual development: PCH7 due to bi-allelic variants in TOE1
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(OMIM # 614969, *613931 [9]) and Joubert syndrome 1 due
to bi-allelic variants in INPP5E (OMIM # 213300, *613037).
Thus, a disorder of sexual development may possibly be a
part of the clinical spectrum of MINPP1, but the number of
cases is too small to draw a definite conclusion. Furthermore,
in family 3 we identified a variant in the androgen receptor
gene AR (OMIM *313700) that may lead to the androgen
insensitivity syndrome (OMIM # 300068) and thus explain
the micropenis regardless of MINPP1.
During submission of this manuscript, a preprint server
publication describing eight other PCH patients with bi-
allelic MINPP1 variants became available [29]. The symp-
toms were comparable such as having, in addition to the clear
pontocerebellar hypoplasia, secondary microcephaly, ataxia,
spasticity, severe developmental delay, epilepsy, vision
issues (cataract, blindness, and others). Compared to other
PCH subtypes (e.g., PCH1B-C or PCH2A), MINPP1 patients
live longer and have slightly milder symptoms. Brain MRI
indicates that the cerebellar hemispheres are often only
mildly affected. Also, white matter and frontal cortex atro-
phy, and the involvement of the basal ganglia could be an
indicator of MINPP1 related PCH.
How MINPP1 aberrations result in a PCH phenotype
remains enigmatic. According to the literature, inositol
polyphosphates (InsPs) were shown to play signaling roles
in the regulation of calcium mobilization, cell growth,
vesicular transport, gene expression, and export of mRNA
and apoptosis [30–34]. MINPP1 is an ER luminal soluble
protein and dephosphorylates InsPs by removing specifi-
cally phosphate group at position 3 and association with
apoptosis has been described extensively [17, 35–41].
MINPP1 is the only ER resident enzyme that can hydrolyze
inositol pentakisphosphate and inositol hexakisphosphate
and it exhibits characteristics of a stress-responsive mole-
cule during ER stress-induced apoptosis regardless of the
underlying involved mechanisms [42]. Accordingly, the
deregulation of apoptosis might be a possible patho-
mechanism in our patients as affected children also showed
enlarged CSF areas suggestive of brain atrophy. However,
this still need more research to be understood. Initially,
MINPP1 was not a convincing candidate gene for PCH as
Minpp1-deficient mice are viable, fertile, and without
obvious defects [43]. However, the identification of four
families with comparable MINPP1 aberrations and a spe-
cific overlapping phenotype make it a very consistent can-
didate gene. Thus, we suggest re-analyzing the mouse
model regarding neurological phenotypes.
An interactor with MINPP1 substrates is the inositol,
1,4,5 triphosphate receptor type 1 (ITPR1). Upon binding
IP3, ITRP1 regulates Ca2+ release from the ER. Bi-allelic
recessive pathogenic variants in ITPR1 are reported to cause
PCH-like phenotype. Also, other genes encoding proteins of
the inositol phosphatase metabolism (e.g., INPP5K, FIG4,
INPP5E) are associated with autosomal recessive syn-
dromes of intellectual disability [44–47]. It seems therefor
plausible that loss of the MINPP1 enzymatic activity would
lead to a comparable disorder. Until now, proteins involved
in metabolic steps pre- or post- MINPP1 (e.g., ITPKA,
ITPKB, ITPKC, ITPK1, and IPKM) are not associated with
phenotypes. However, considering the above-mentioned
arguments, it is not unlikely that they will be linked to
human disease in the next future.
Although we still do not have clear functional proof of
causality between MINPP1 variants identified in four
families and the observed clinical phenotype, based on the
noncoincidental overlap of features and genotypes of the
affected children as well as the relevance of the inositol
phosphatase metabolism to neurological disorders (includ-
ing PCH), we conclude that sequence variants in MINPP1
are associated with a new form of syndromic pontocer-
ebellar hypoplasia.
Note
After submission of this paper, a fifth family with a
homozygous MINPP1 frameshift variant c.1401delG
p.(Ser468Valfs*10) in MINPP1 and similar symptoms was
identified. Patient 5-1 presented at 12 months of age with
global developmental delay, brain malformation, micro-
cephaly, epilepsy, feeding difficulty, laryngomalacia, and
hypogonadism. He was full born to consanguineous par-
ents. The pregnancy was unremarkable (weight 3.12 kg). He
developed seizures at 4 months of age. The patient had
multiple episodes of aspiration pneumonia and transitioned
to nasogastric feeding. At 12 months he presented with
hypopigmented oval macula and severe microcephaly (head
circumference 41 cm, −4.46 SD) and an upturned nose. His
global motor development was delayed and vision was low.
Brain MRI at 16 months of age showed structural
abnormalities of the posterior fossa including marked
hypoplasia of the brainstem, cerebellar hemispheres and
cerebella peduncles. He had signal abnormality of the deep
gray matter and hippocampi, posterior predominant peri-
ventricular white matter volume loss, thinning of the pos-
terior corpus callosum, and signal abnormality within the
bilateral cerebellar hemispheres
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